Indivior Pharmaceuticals, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Indivior Pharmaceuticals, Inc. changed its legal name to Supernus, Inc. (effective November 2, 2026) and simultaneously entered into a $650 million term loan credit agreement with Citibank as administrative agent and five joint lead arrangers (Bank of America, PNC Capital Markets, Truist Securities, U.S. Bank). The facility matures in 5 years (November 2031, or 91 days before convertible notes due date, whichever is earlier) with quarterly amortization starting March 2027 ($4.1M quarterly initially, stepping up to $8.1M then $12.2M quarterly). This refinances prior UBS credit line debt and funds the Supernus merger transaction completed on the Effective Date.
Why this rating
Major refinancing and corporate reorganization post-merger; $650M facility represents ~36% of company's ~$1.8B market cap—material scale. Name change purely administrative. Debt terms and covenant structure are ordinary; no transformational strategic shift evident. Refinancing is routine post-M&A. Significance driven by transaction scale and leverage restructuring, not extraordinary business risk.
Price action (we called it neutral)
before filing · preread $35.37 ▼ 0.16% | at our read · unknown $35.42 | +10 min · unknown $35.84 ▲ 1.17% | +30 min · unknown $36.15 ▲ 2.05% | +1 hr · unknown $36.36 ▲ 2.64% | +4 hrs pending |
The stock had already moved +0.16% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.